BeiGene, Ltd. Files 2024 10-K
Ticker: BEIGF · Form: 10-K · Filed: Feb 27, 2025 · CIK: 1651308
| Field | Detail |
|---|---|
| Company | Beigene, LTD. (BEIGF) |
| Form Type | 10-K |
| Filed Date | Feb 27, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, annual-report, pharmaceuticals
TL;DR
BeiGene filed its 2024 10-K. Full financials out.
AI Summary
BeiGene, Ltd. filed its 2024 10-K on February 27, 2025, detailing its operations for the fiscal year ending December 31, 2024. The company, operating in the pharmaceutical preparations sector, is headquartered in Grand Cayman, Cayman Islands. This filing provides a comprehensive overview of its financial performance and business activities for the year.
Why It Matters
This 10-K filing provides investors and stakeholders with crucial financial and operational details for BeiGene, Ltd. for the fiscal year 2024, enabling informed investment decisions.
Risk Assessment
Risk Level: medium — The filing is a standard annual report and does not inherently indicate new risks.
Key Players & Entities
- BeiGene, Ltd. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-02-27 (date) — Filing date
- Grand Cayman, Cayman Islands (location) — Company headquarters
FAQ
What is BeiGene, Ltd.'s primary industry classification?
BeiGene, Ltd. is classified under Pharmaceutical Preparations [2834].
When did BeiGene, Ltd. file its 2024 10-K report?
BeiGene, Ltd. filed its 2024 10-K report on February 27, 2025.
What is the fiscal year end for BeiGene, Ltd. as reported in this filing?
The fiscal year end for BeiGene, Ltd. is December 31.
What is the SEC file number for BeiGene, Ltd.'s 10-K filing?
The SEC file number for BeiGene, Ltd.'s 10-K filing is 001-37686.
Where is BeiGene, Ltd.'s business address listed?
BeiGene, Ltd.'s business address is listed as C/O Mourant Governance Services (Cayman), 94 Solaris Avenue, Camana Bay, Grand Cayman, E9, KY1-1108.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on February 27, 2025 regarding BeiGene, Ltd. (BEIGF).